Áö¹æ°£Áúȯ (´ë»çÀÌ»óÁö¹æ°£Áõ ¹× ¾ËÄÚ¿Ã)¿¡ ´ëÇÑ Àӻ󿬱¸ ¹× ½Å¾à°³¹ß ¿¬±¸¸¦ ¼öÇàÇϰí ÀÖ½À´Ï´Ù.
´ë»çÀÌ»óÁö¹æ°£Áúȯ(ºñ¾ËÄÚ¿ÃÁö¹æ°£)¿¡ ´ëÇÏ¿© Àӻ󿬱¸ ¹× ½Å¾à°³¹ß°ú °ü·ÃµÈ ¿¬±¸¸¦ ¼öÇàÁß. Áö¹æ°£Áúȯ ¾à¹° °³¹ßÀ» À§ÇÏ¿© Ÿ±êÀ» ¹ß±¼, ÀüÀӻ󿬱¸, ÀüÀÓ»ó µ¶¼º, ÀÓ»ó 1~3»ó±îÁö Áö¹æ°£Áúȯ ¾à¹°°³¹ß¿¡ ´ëÇÑ ÀüÁֱ⿡ °ÉÃÄ ¿¬±¸¸¦ ÁøÇàÇϰí ÀÖÀ½.
| Á¦ ¸ñ | Diagnostic Performance of Noninvasive Tests in Patients with MetALD in a Health Check-up Cohort | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era? | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease. | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Is lifestyle modification effective for individuals with high fibrosis-4 index without an additional 2nd tier test? | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | |
Áö¹æ°£Áúȯ ¼¼°è ÃÖ°í Àú¸íÇмúÁö (»óÀ§ 5% À̳») 10Æí ÀÌ»ó
ÃøÀºÁö½É

ÇѾç´ëÇб³º´¿øÀº 1972³â °³¿ø ÀÌÈÄ, »ç¶ûÀÇ ½Çõ Á¤½ÅÀ» ¹ÙÅÁÀ¸·Î ÀÇ·áÀÇ ÇѰ迡 µµÀüÇϸç, Çõ½ÅÀûÀÎ ¼º°ú¸¦ ÀÌ·ï¿Ô½À´Ï´Ù. ·ù¸¶Æ¼½º ¹× ½Å°æ°èÁúȯ Ä¡·áÀÇ ¼±µµ º´¿ø°ú ÁßÁõ ¾ÏÁúȯ µî¿¡ ÃֽеðÁöÅÐ Çõ½Å ±â¼ú°ú ¿¬±¸Á߽ɺ´¿øÀ¸·Î¼ AI, ºòµ¥ÀÌÅÍ µîÀ» Ȱ¿ëÇÑ ÀÓ»ó ¿¬±¸¸¦ °ÈÇÏ¸ç ¹Ì·¡ ÀÇÇÐÀ» À̲ø°í ÀÖ½À´Ï´Ù.
¼¿ïƯº°½Ã ¼ºµ¿±¸ ¿Õ½Ê¸®·Î 222-1